Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29


Unique Sjögren's syndrome patient subsets defined by molecular features.

James JA, Guthridge JM, Chen H, Lu R, Bourn RL, Bean K, Munroe ME, Smith M, Chakravarty E, Baer AN, Noaiseh G, Parke A, Boyle K, Keyes-Elstein L, Coca A, Utset T, Genovese MC, Pascual V, Utz PJ, Holers VM, Deane KD, Sivils KL, Aberle T, Wallace DJ, McNamara J, Franchimont N, St Clair EW.

Rheumatology (Oxford). 2019 Sep 8. pii: kez335. doi: 10.1093/rheumatology/kez335. [Epub ahead of print]


Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals.

Jog NR, Young KA, Munroe ME, Harmon MT, Guthridge JM, Kelly JA, Kamen DL, Gilkeson GS, Weisman MH, Karp DR, Gaffney PM, Harley JB, Wallace DJ, Norris JM, James JA.

Ann Rheum Dis. 2019 Sep;78(9):1235-1241. doi: 10.1136/annrheumdis-2019-215361. Epub 2019 Jun 19.


Immunologic findings precede rapid lupus flare after transient steroid therapy.

Lu R, Guthridge JM, Chen H, Bourn RL, Kamp S, Munroe ME, Macwana SR, Bean K, Sridharan S, Merrill JT, James JA.

Sci Rep. 2019 Jun 13;9(1):8590. doi: 10.1038/s41598-019-45135-w.


Screening characteristics for enrichment of individuals at higher risk for transitioning to classified SLE.

Young KA, Munroe ME, Guthridge JM, Kamen DL, Gilkensen GS, Harley JB, Weisman MH, Karp DR, Wallace DJ, James JA, Norris JM.

Lupus. 2019 Apr;28(5):597-606. doi: 10.1177/0961203319834675. Epub 2019 Mar 7.


Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus.

Young KA, Munroe ME, Harley JB, Guthridge JM, Kamen DL, Gilkensen GS, Weisman MH, Karp DR, Wallace DJ, James JA, Norris JM.

Lupus. 2018 Aug;27(9):1524-1531. doi: 10.1177/0961203318778368. Epub 2018 May 28.


Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus.

Kheir JM, Guthridge CJ, Johnston JR, Adams LJ, Rasmussen A, Gross TF, Munroe ME, Bourn RL, Sivils KL, Guthridge JM, Weisman MH, Wallace DJ, Anaya JM, Rojas Villarraga A, Jarvis JN, Harley JB, James JA.

Lupus Sci Med. 2018 Feb 27;5(1):e000247. doi: 10.1136/lupus-2017-000247. eCollection 2018.


Association of IFIH1 and pro-inflammatory mediators: Potential new clues in SLE-associated pathogenesis.

Munroe ME, Pezant N, Brown MA, Fife DA, Guthridge JM, Kelly JA, Wiley G, Gaffney PM, James JA, Montgomery CG.

PLoS One. 2017 Feb 24;12(2):e0171193. doi: 10.1371/journal.pone.0171193. eCollection 2017.


Pathways of impending disease flare in African-American systemic lupus erythematosus patients.

Munroe ME, Vista ES, Merrill JT, Guthridge JM, Roberts VC, James JA.

J Autoimmun. 2017 Mar;78:70-78. doi: 10.1016/j.jaut.2016.12.005. Epub 2017 Feb 2.


Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls.

Aberle T, Bourn RL, Munroe ME, Chen H, Roberts VC, Guthridge JM, Bean K, Robertson JM, Sivils KL, Rasmussen A, Liles M, Merrill JT, Harley JB, Olsen NJ, Karp DR, James JA.

Arthritis Care Res (Hoboken). 2017 Dec;69(12):1780-1788. doi: 10.1002/acr.23201. Epub 2017 Nov 14.


Systemic lupus erythematosus biomarkers: the challenging quest.

Arriens C, Wren JD, Munroe ME, Mohan C.

Rheumatology (Oxford). 2017 Apr 1;56(suppl_1):i32-i45. doi: 10.1093/rheumatology/kew407. Review.


Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features.

Munroe ME, Young KA, Kamen DL, Guthridge JM, Niewold TB, Costenbader KH, Weisman MH, Ishimori ML, Wallace DJ, Gilkeson GS, Karp DR, Harley JB, Norris JM, James JA.

Arthritis Rheumatol. 2017 Mar;69(3):630-642. doi: 10.1002/art.40004.


Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies.

Lu R, Munroe ME, Guthridge JM, Bean KM, Fife DA, Chen H, Slight-Webb SR, Keith MP, Harley JB, James JA.

J Autoimmun. 2016 Nov;74:182-193. doi: 10.1016/j.jaut.2016.06.001. Epub 2016 Jun 20.


Impact of heart rate variability, a marker for cardiac health, on lupus disease activity.

Thanou A, Stavrakis S, Dyer JW, Munroe ME, James JA, Merrill JT.

Arthritis Res Ther. 2016 Sep 2;18:197. doi: 10.1186/s13075-016-1087-x.


Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus.

Young KA, Munroe ME, Guthridge JM, Kamen DL, Niewold TB, Gilkeson GS, Weisman MH, Ishimori ML, Kelly J, Gaffney PM, Sivils KH, Lu R, Wallace DJ, Karp DR, Harley JB, James JA, Norris JM.

Ann Rheum Dis. 2017 Jan;76(1):153-158. doi: 10.1136/annrheumdis-2016-209157. Epub 2016 Jun 9.


Unique Inflammatory Mediators and Specific IgE Levels Distinguish Local from Systemic Reactions after Anthrax Vaccine Adsorbed Vaccination.

Garman L, Smith K, Muns EE, Velte CA, Spooner CE, Munroe ME, Farris AD, Nelson MR, Engler RJ, James JA.

Clin Vaccine Immunol. 2016 Aug 5;23(8):664-71. doi: 10.1128/CVI.00092-16. Print 2016 Aug.


Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.

Munroe ME, Lu R, Zhao YD, Fife DA, Robertson JM, Guthridge JM, Niewold TB, Tsokos GC, Keith MP, Harley JB, James JA.

Ann Rheum Dis. 2016 Nov;75(11):2014-2021. doi: 10.1136/annrheumdis-2015-208140. Epub 2016 Jan 25.


Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity.

Slight-Webb S, Lu R, Ritterhouse LL, Munroe ME, Maecker HT, Fathman CG, Utz PJ, Merrill JT, Guthridge JM, James JA.

Arthritis Rheumatol. 2016 Oct;68(10):2492-502. doi: 10.1002/art.39706.


Genetics of Lupus Nephritis: Clinical Implications.

Munroe ME, James JA.

Semin Nephrol. 2015 Sep;35(5):396-409. doi: 10.1016/j.semnephrol.2015.08.002. Review.


High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination.

Kaur K, Zheng NY, Smith K, Huang M, Li L, Pauli NT, Henry Dunand CJ, Lee JH, Morrissey M, Wu Y, Joachims ML, Munroe ME, Lau D, Qu X, Krammer F, Wrammert J, Palese P, Ahmed R, James JA, Wilson PC.

PLoS One. 2015 May 7;10(5):e0125618. doi: 10.1371/journal.pone.0125618. eCollection 2015.


Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare.

Munroe ME, Vista ES, Guthridge JM, Thompson LF, Merrill JT, James JA.

Arthritis Rheumatol. 2014 Jul;66(7):1888-99. doi: 10.1002/art.38573.


Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways.

Vaughn SE, Kottyan LC, Munroe ME, Harley JB.

J Leukoc Biol. 2012 Sep;92(3):577-91. doi: 10.1189/jlb.0212095. Epub 2012 Jun 29. Review.


Anti-inflammatory effects of the neurotransmitter agonist Honokiol in a mouse model of allergic asthma.

Munroe ME, Businga TR, Kline JN, Bishop GA.

J Immunol. 2010 Nov 1;185(9):5586-97. doi: 10.4049/jimmunol.1000630. Epub 2010 Oct 1.


Functional roles for T cell CD40 in infection and autoimmune disease: the role of CD40 in lymphocyte homeostasis.

Munroe ME.

Semin Immunol. 2009 Oct;21(5):283-8. doi: 10.1016/j.smim.2009.05.008. Epub 2009 Jun 17. Review.


A costimulatory function for T cell CD40.

Munroe ME, Bishop GA.

J Immunol. 2007 Jan 15;178(2):671-82.


Cooperation between TNF receptor-associated factors 1 and 2 in CD40 signaling.

Xie P, Hostager BS, Munroe ME, Moore CR, Bishop GA.

J Immunol. 2006 May 1;176(9):5388-400.


Expression of the cytoplasmic tail of LMP1 in mice induces hyperactivation of B lymphocytes and disordered lymphoid architecture.

Stunz LL, Busch LK, Munroe ME, Sigmund CD, Tygrett LT, Waldschmidt TJ, Bishop GA.

Immunity. 2004 Aug;21(2):255-66.


Early alteration in leukocyte populations and Th1/Th2 function in ethanol-consuming mice.

Starkenburg S, Munroe ME, Waltenbaugh C.

Alcohol Clin Exp Res. 2001 Aug;25(8):1221-30.


Supplemental Content

Loading ...
Support Center